These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 17599137)

  • 1. [What drug companies actually do].
    Tonby K
    Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1806. PubMed ID: 17599137
    [No Abstract]   [Full Text] [Related]  

  • 2. Indian biogenerics industry emerges.
    Jayaraman KS
    Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378
    [No Abstract]   [Full Text] [Related]  

  • 3. Long way down--pharmaceutical companies fear falling off 'patent cliff'.
    Sklan A
    Pharm Pat Anal; 2012 Jul; 1(3):240. PubMed ID: 24386667
    [No Abstract]   [Full Text] [Related]  

  • 4. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 5. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 6. Generics battle brand names over mortality of drug patents.
    Betz R
    J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
    [No Abstract]   [Full Text] [Related]  

  • 7. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract]   [Full Text] [Related]  

  • 8. The Eleventh Circuit holds that agreements in which pharmaceutical companies pay generic companies not to compete may be valid.
    Garrigues A
    J Law Med Ethics; 2004; 32(1):181-4. PubMed ID: 15152443
    [No Abstract]   [Full Text] [Related]  

  • 9. Reforming Canada's Access to Medicines Regime.
    Elliott R
    CMAJ; 2007 Jul; 177(3):270-1. PubMed ID: 17664453
    [No Abstract]   [Full Text] [Related]  

  • 10. Reinventing an industry.
    Mandavilli A
    Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817
    [No Abstract]   [Full Text] [Related]  

  • 11. Statin utilisation--recognising the role of the invisible hand.
    Minhas R
    Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171
    [No Abstract]   [Full Text] [Related]  

  • 12. US policy may encourage counterfeit drugs.
    Bouchie A
    Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
    [No Abstract]   [Full Text] [Related]  

  • 13. Delaying generic competition--corporate payoffs and the future of Plavix.
    Shuchman M
    N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
    [No Abstract]   [Full Text] [Related]  

  • 14. TRIPS: whose interests are being served?
    Kamal M; Bailey M
    Lancet; 2003 Jul; 362(9380):260. PubMed ID: 12892952
    [No Abstract]   [Full Text] [Related]  

  • 15. Trade deal to curb generic-drug use.
    Maxmen A
    Nature; 2012 Sep; 489(7414):16-7. PubMed ID: 22962700
    [No Abstract]   [Full Text] [Related]  

  • 16. Canada to change patent law to allow export of cheap drugs.
    Kondro W
    Lancet; 2003 Oct; 362(9392):1290. PubMed ID: 14577437
    [No Abstract]   [Full Text] [Related]  

  • 17. Handle with care.
    Macilwain C
    Nature; 2006 Apr; 440(7087):990-1. PubMed ID: 16625170
    [No Abstract]   [Full Text] [Related]  

  • 18. [Free trade agreements make the drugs more expensive].
    Jeppsson A
    Lakartidningen; 2009 Nov 18-24; 106(47):3181. PubMed ID: 20082499
    [No Abstract]   [Full Text] [Related]  

  • 19. Who's really raising drug prices?
    Zagorin A
    Time; 1999 Mar; 153(9):46-8. PubMed ID: 10346086
    [No Abstract]   [Full Text] [Related]  

  • 20. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.